EU MDR Execution Risk: Why Regulatory Strategy Has Become a Competitive Advantage

Regulatory execution under EU MDR is now a primary determinant of time-to-market, capital efficiency, and commercial viability for medical device companies.

The implementation of EU MDR has materially increased the complexity of regulatory approval processes across all device classes.

Notified body capacity constraints, combined with heightened documentation requirements, have extended certification timelines and introduced execution risk across development pipelines. As a result, regulatory strategy is no longer a compliance function—it is a core strategic capability.

Companies that invest early in clinical evidence planning, documentation quality, and proactive engagement with notified bodies are better positioned to navigate this environment.

Conversely, reactive approaches continue to result in delays, increased costs, and potential loss of market access.